OKYO Pharma Limited (OKYO) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, OKYO carries an RQD Score of 52 and a letter grade of D+, labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are scored as follows:

• Fundamental Cash Engine: 12 / 20 (ROIC 0%; FCF yield 0%). Per the market data, return on invested capital and free cash flow yield are both reported at 0%, indicating the rating's cash-generation pillar is weak on the figures supplied.
• Whale 13F Flow: 8 / 20 (institutional accumulation and options positioning). This is a below-midpoint reading; the source does not provide the underlying 13F detail to explain it.
• Insider Conviction: 9 / 20 (SEC Form 4 and Congressional PTR cluster flow). Also below midpoint; the individual trade records are not provided.
• Macro Regime Fit: 10 / 20 (beta 1.0; sector sensitivity). Per the market data, beta is 1.0, meaning the stock is reported as moving in line with the market.
• Forensic Balance Sheet: 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). This is the strongest pillar, though still short of a high score.

For a prospective investor evaluating the stock today, the rating's implication is that the cash-generation and flow-based signals are weak, while the balance sheet metrics are comparatively the most supportive. The rating's own verdict is a trim/sell posture. Any upside case would have to rest on factors outside the reported cash engine, such as the clinical catalysts described in the news wire section, which the rating does not quantify.

OKYO Pharma Limited is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, its market capitalization is $0.1B. Per the news wire, the company is advancing urcosimod for neuropathic corneal pain through a Phase 3 pivotal trial, with first patients reported as enrolled. The source data does not describe its customers, revenue model, or how it generates money.

• Phase 3 enrollment (primary catalyst): Multiple news items report that first patients have enrolled in the Phase 3 pivotal trial of urcosimod for neuropathic corneal pain, described as a 12-week trial. This is the principal positive development in the feed.
• Analyst-sentiment coverage: A Globe and Mail item references conflicting analyst sentiment across several healthcare names, with OKYO appearing only as a tagged symbol; no OKYO-specific analyst view is given.
• Market-wire items: Several entries are aggregator or generic market pieces (Stocktwits, Yahoo! Finance Canada seasonal chart for a different ticker, Quiver Quantitative), and carry no independent fundamental information.
• Risk watch items: Per the market data, the price is reported as down 2% with volume of 107,543. The stock trades near the low end of its 52-week range ($1.26 to $3.2).
• Proprietary signals: None reported in the Butterfly graph.

Per the Butterfly Supply-Chain Graph, the supply chain is reported as "NONE," with no butterfly links and no proprietary signals. Accordingly, no upstream or downstream dependencies, sector correlation mappings, or second-order bottlenecks can be identified from the source data. An investor should note that the clinical program's progress is the only substantive operational driver visible in the sources, but no supplier, partner, or manufacturing dependency is documented.

• What are the company's reported revenues, operating income, and net income across recent periods, given that the financials section is empty?
• What is the cash runway and current debt level underlying the 0.5 Debt/Equity figure cited in the rating?
• What specific institutional 13F and insider Form 4 transactions produced the 8/20 and 9/20 flow and conviction scores?
• What are the expected timing and endpoints for the Phase 3 urcosimod trial, and what partnering or financing arrangements support it?
• Does the company have any analyst coverage, and if so, what are the rating and price target distributions?